LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC (LOST- B) Trial
Status:
Not yet recruiting
Trial end date:
2027-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to compare the effectiveness and safety of two standard
of care treatments in people who have been diagnosed with hepatocellular carcinoma (HCC).This
research study is being done to compare atezolizumab/bevacizumab to locoregional therapy with
either transarterial chemoembolization (TACE) or transarterial radioembolization (TARE).